Date: 2017-12-13
Type of information: Financing round
Company: Myonexus Therapeutics (USA - OH)
Investors: The Jain Foundation (USA) GFB ONLUS (USA) Rev1 Ventures (USA - OH) investors from the LGMD community.
Amount: $2.5 million
Funding type: seed financing round
Planned used:
- The seed financing will enable Myonexus to initiate a systemic Phase 1/2a clinical trial of MYO-101, the company’s gene therapy candidate for treating LGMD2E (beta-sarcoglycanopathy), in early 2018. Myonexus’ pipeline also includes MYO-102, a gene therapy candidate for LGMD2D (alpha-sarcoglycanopathy) currently completing a Phase 1/2a clinical trial, MYO-201, a gene therapy candidate for LGMD2B (dysferlinopathy) currently in Phase 1, MYO-103, a preclinical gene therapy candidate for LGMD2C (gamma-sarcoglycanopathy), and MYO-301, a preclinical gene therapy candidate for LGMD2L (anoctamin 5).
Others:
- • On December 13, 2017, Myonexus Therapeutics, a clinical-stage biotechnology company developing transformative gene therapies for limb-girdle muscular dystrophies (LGMDs), announced the completion of a $2.5 million seed financing. The company is committed to accelerating development of five gene therapies pioneered within the lab of Louise Rodino-Klapac, Ph.D. and under clinical guidance by Jerry Mendell, M.D., each a Principal Investigator at Nationwide Children’s Hospital Center for Gene Therapy in Columbus, Ohio, USA. CincyTech, LLC, Rev1 Ventures, The Jain Foundation, and GFB ONLUS joined initial investors from the LGMD community.
Therapeutic area: Rare diseases - Genetic diseases - Neuromuscular diseases
Is general: Yes
